Loading…
AZN
Astrazeneca PLC
NYSE· Healthcare· Drug Manufacturers - General· CUSIP G0593M107
$172.57+2.45%Price as of Oct 23, 00:42 UTC · updated once a day, after the close
At a glance
Astrazeneca PLC (AZN) is listed on NYSE and classified in Drug Manufacturers - General, part of the Healthcare sector. It is headquartered in Cambridge, United Kingdom and has 96,100 employees. The company is worth $267.64B and trades at 25.8x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $58.74B in fiscal 2025, up 8.6% from the year before. Net income was $10.23B. The share price is 18.9% below its 52-week high of $212.71. It pays a dividend yielding 1.85%. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Ken Griffin (Citadel Advisors), at $183.94M. In that quarter, 2 of them opened or added to the position and 3 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $267.64B
- P/E
- 25.8x
- Forward P/E
- 15.2x
- P/B
- 5.3x
- Dividend yield
- 1.85%
- Payout
- 47.83%
- EPS
- $6.69
- ROE
- 21.96%
- Profit margin
- 17.02%
- Revenue growth
- +6.40%
- Beta
- 0.21
- 52-week high
- $212.71
- 52-week low
- $153.41
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Ken GriffinReducedCitadel Advisors · Q2 2026$183.94M970.04K shares · 0.1% of portfolio- Steve CohenReducedPoint72 Asset Management · Q2 2026$134.92M711.55K shares · 0.2% of portfolio
- Israel EnglanderReducedMillennium Management · Q2 2026$110.34M581.91K shares · 0.1% of portfolio
- Cliff AsnessAddedAQR Capital Management · Q2 2026$75.05M400.94K shares · 0.0% of portfolio
- Two SigmaAddedTwo Sigma Investments · Q2 2026$62.4M329.09K shares · 0.0% of portfolio
Price over time
▲ +50.8% over 5Y.
today you would have $1,461.25▲ +46.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $183.86 | $131.04 | $134.70 | $135.60 | |
| P/E | 32.2x | 28.1x | 29.1x | 35.4x | 64.3x |
| P/S | 4.6x | 4.9x | 3.8x | 4.6x | 4.7x |
| P/B | 5.5x | 5.9x | 5.0x | 5.3x | 5.7x |
| EPS | $6.54 | $4.50 | $3.81 | $2.11 | |
| Dividend yield | 2.15% | 1.70% | 2.27% | 2.15% | 2.14% |
| Payout | 71.06% | 47.86% | 66.00% | 76.12% | 137.44% |
| Profit margin | 13.00% | 17.41% | 13.01% | 13.00% | 7.41% |
| ROE | 16.23% | 21.01% | 17.25% | 15.21% | 8.88% |
Median of the years shown; P/E years above 200x are left out.
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
$69.86
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings
$179.66
Earnings growing 25.0% a year plus a 1.9% dividend yield. Growth capped at 25%.
Earnings
$162.47
Median P/E of 24.3 among peers in the sector.
Earnings
$215.67
Median P/E of 32.2 across this company’s own years on record.
Cash flow
$176.04
Cash flow growing 15.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
$161.79
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
Dividends
$209.08
Dividend growing 5.4% a year against a 7.0% required return, from the stock’s beta.
How the average is calculated
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
Earnings $156.91 (avg. of 4)+Cash flow $176.04+Operating $161.79+Dividends $209.08÷ 4 =$175.96
$175.96
7 methods answered, across 4 families.
$131.97
Room for errors in the reported numbers.
$172.57
+2.0% from the average.
Models, not forecasts, and not investment advice. How each formula works →
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TMOThermo Fisher Scientific Inc | $676.54 | 35.7x | 4.6x | 0.28% | 13.38% | $250.15B |
| AMGNAmgen Inc | $447.28 | 27.2x | 20.7x | 2.25% | 91.47% | $241.81B |
| NVSNovartis AG | $156.27 | 23.6x | 7.1x | 3.03% | 30.35% | $297.02B |
| MRKMerck & Co., Inc. | $147.24 | 116.9x | 8.7x | 2.31% | 6.96% | $363.27B |
| GILDGilead Sciences Inc | $157.19 | — | 16.5x | 2.09% | -20.68% | $194.91B |
| UNHUnitedhealth Group Inc | $424.98 | 26.8x | 3.7x | 2.18% | 15.77% | $381.46B |
About the company
- 96,100
- Cambridge, United Kingdom